Oncologist Interested in Aging And Oncology
Mikhail Blagosklonny is a oncologist whom is also an expert in aging and was formerly a professor of oncology. He holds a MD in internal medicine, and has contributed a great deal of research as a scientist.
One area which he is an expert in is in creating a hypothesis for aging. TOR signaling, according to Mikhail, is the huge culprit behind aging and cancer. Rapamycin is a popular cancer drug that has a immunosuppressant function and Mikhail advocates for it’s use in cancer and aging.
The target of the Rapamycin drug is not active in contact-inhibited cells. This prevents the mTOR from becoming active in contact-inhibited cells. Converting to senescence is suppressed in cases where there are contact-inhibited cells. Follow Mikhail on Google Scholar.
Plans for Oncology Research
Mikhail’s aim is to treat cancer in a cost-effective way which is less excruciating than the current methods on the market. The aim is to destroy cancer cells and do so without destroying normal body cells.
He believes that there is a connection between cancer and aging, Furthermore, he believes that cancer is common in older individuals, which is what he uses to cite as evidence for his theory that connects cancer to aging.
Professor at Roswell Park Cancer Institute Working as Editor in Chief
Mikhail Blagosklonny is currently a professor at Roswell Park Cancer Institute and is working as an editor in chief for 3 different publications: Oncotarget, Aging, and Cell Cycle. He has 336 publications for which he is either the primary author, secondary author or an author on. This also gives him a total of 29050 citations, 12486 of which were since 2013. He is specifically interested in the cellular and molecular causes of human aging. Read more on Impact Journals.
Diverse Cross Section of Papers In Cancer, Aging
His papers represent a diverse cross section of scholarship, and demonstrate his abilities as a prominent researcher in his field. He is focused on cancer and aging research, including anti-aging properties of the drugs which he is interested in studying.
Editor in Chief of Oncotarget Publication With Hyperfuction Aging Theory
As the editor-in-chief of Oncotarget, he is an author of a theory known as the aging hyperfunction theory. This states that aging is caused by the accumulation of damage to the body, in the form of oxidative stress. Overactivity of metabolic processes causes an acceleration in the rate of age-related processes that lead to mortality.
M.D. and PhD Academic Background and Professional Background
His academic background includes a M.D. and PhD in internal medicine, experimental medicine, and oncology. He is also an Associate Professor at New York Medical College and Chairman of The Capital Group Companies, and a Board Member of Differentiation Journal Editorial Board.